LivingGLP1
Study S000918

Effect of Semaglutide on the Inflammatory Response and Clinical Course of Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus

Included trial: extracted dataClinicalTrials.gov recordStudy Protocol (PDF)Statistical Analysis Plan (PDF)Informed Consent Form (PDF)

Registration

Registration
NCT06475586
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE4
Masking
DOUBLE
Status
COMPLETED
Enrollment
30
Start
2023-05-03
Primary completion
2024-03-01
Lead sponsor
University of Banja Luka
Conditions
Psoriasis Vulgaris; Diabetes Type 2
Interventions
DRUG:Semaglutide
Results posted
FALSE
Individual participant data sharing
YES

Registered primary outcomes

  • clinical characteristics of patients with psoriasis [up to 12 weeks]
  • Determine BMI Body Mass Index [up to 12 weeks]
  • Serum values of TNFa, IL-1b, IL-6, IL-17 and IL-23 [up to12 weeks]
  • Correlation between the course and prognosis of the disease after the treatment [up to 12 weeks]
  • Change in HgbA1C, [up to 12 weeks]
  • lipid status, change in Total cholesterol (TC), low-density lipoprotein(LDL), high-density lipoprotein (HDL) and triglicerides [up to 12 weeks]
  • fasting insulin [up to 12 weeks]
  • Change in inflammation marker level: CRP, [up to 12 weeks]
  • fasting glycemia [up to 12 weeks]
  • urate [up to 12 weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0007787GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Nauck MA, Molecular metabolism
2021Narrative reviewPMID 33068776DOIregistry reference RESULT:33068776
R0016470Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient.
Costanzo G, Endocrinology, diabetes & metabolism case reports
2021OtherPMID 34463640DOIregistry reference RESULT:34463640